Trial · NCT04015518
Results by group45
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 45
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI) at Week 16 From Baseline | Placebo | -33.6 | 95% Confidence Interval -43.5 to -23.7 | Percentage of change in PPP ASI | |
| The Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI) at Week 16 From Baseline | Spesolimab 'Speso Low' | -44.2 | 95% Confidence Interval -57.8 to -30.6 | Percentage of change in PPP ASI | |
| The Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI) at Week 16 From Baseline | Spesolimab 'Speso Medium-low' | -48.3 | 95% Confidence Interval -61.8 to -34.7 | Percentage of change in PPP ASI | |
| The Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI) at Week 16 From Baseline | Spesolimab 'Speso Medium-high' | -46.2 | 95% Confidence Interval -59.9 to -32.6 | Percentage of change in PPP ASI | |
| The Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI) at Week 16 From Baseline | Spesolimab 'Speso High' | -38.9 | 95% Confidence Interval -48.5 to -29.3 | Percentage of change in PPP ASI | |
| Change From Baseline in Palmoplantar Pustulosis Pain Visual Analogue Scale (VAS) Score at Week 4 | Placebo | -9.3 | 95% Confidence Interval -17.0 to -1.6 | Score on a scale | |
| Change From Baseline in Palmoplantar Pustulosis Pain Visual Analogue Scale (VAS) Score at Week 4 | Spesolimab 'Speso Low' | -15.4 | 95% Confidence Interval -26.1 to -4.8 | Score on a scale | |
| Change From Baseline in Palmoplantar Pustulosis Pain Visual Analogue Scale (VAS) Score at Week 4 | Spesolimab 'Speso Medium-low' | -14.7 | 95% Confidence Interval -25.7 to -3.8 | Score on a scale | |
| Change From Baseline in Palmoplantar Pustulosis Pain Visual Analogue Scale (VAS) Score at Week 4 | Spesolimab 'Speso Medium-high' | -12.8 | 95% Confidence Interval -23.5 to -2.1 | Score on a scale | |
| Change From Baseline in Palmoplantar Pustulosis Pain Visual Analogue Scale (VAS) Score at Week 4 | Spesolimab 'Speso High' | -18.7 | 95% Confidence Interval -26.3 to -11.1 | Score on a scale | |
| Change From Baseline in Palmoplantar Pustulosis Pain Visual Analogue Scale (VAS) Score at Week 16 | Placebo | -14.7 | 95% Confidence Interval -22.7 to -6.7 | Score on a scale | |
| Change From Baseline in Palmoplantar Pustulosis Pain Visual Analogue Scale (VAS) Score at Week 16 | Spesolimab 'Speso Low' | -18.7 | 95% Confidence Interval -29.8 to -7.7 | Score on a scale | |
| Change From Baseline in Palmoplantar Pustulosis Pain Visual Analogue Scale (VAS) Score at Week 16 | Spesolimab 'Speso Medium-low' | -13.8 | 95% Confidence Interval -24.8 to -2.8 | Score on a scale | |
| Change From Baseline in Palmoplantar Pustulosis Pain Visual Analogue Scale (VAS) Score at Week 16 | Spesolimab 'Speso Medium-high' | -18.9 | 95% Confidence Interval -30.0 to -7.8 | Score on a scale | |
| Change From Baseline in Palmoplantar Pustulosis Pain Visual Analogue Scale (VAS) Score at Week 16 | Spesolimab 'Speso High' | -22.4 | 95% Confidence Interval -30.2 to -14.6 | Score on a scale | |
| Palmoplantar Pustulosis Severity Index (PPP SI) Change From Baseline at Week 16 | Placebo | -2.7 | 95% Confidence Interval -3.4 to -2.0 | Score on a scale | |
| Palmoplantar Pustulosis Severity Index (PPP SI) Change From Baseline at Week 16 | Spesolimab 'Speso Low' | -3.3 | 95% Confidence Interval -4.3 to -2.4 | Score on a scale | |
| Palmoplantar Pustulosis Severity Index (PPP SI) Change From Baseline at Week 16 | Spesolimab 'Speso Medium-low' | -3.2 | 95% Confidence Interval -4.2 to -2.3 | Score on a scale | |
| Palmoplantar Pustulosis Severity Index (PPP SI) Change From Baseline at Week 16 | Spesolimab 'Speso Medium-high' | -3.5 | 95% Confidence Interval -4.4 to -2.5 | Score on a scale | |
| Palmoplantar Pustulosis Severity Index (PPP SI) Change From Baseline at Week 16 | Spesolimab 'Speso High' | -2.8 | 95% Confidence Interval -3.4 to -2.1 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04015518/results